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Summary 
Nutraceuticals constitute a group of functional foods that provide added health bene-
fits for various disorders including inflammatory bowel disease (IBD) and colorectal 
cancer (CRC). The main groups of nutraceuticals include probiotics, prebiotics, omega 
3 and antioxidants. Studies on Nutraceutical showed that this type of food possessed 
similar proprieties to drugs but with the benefit of not having side effects.  
This mini review shows that probiotics and prebiotics, when administered simultane-
ously with traditional therapies, reduce IBD symptoms and reduce synthesis of en-
zymes probably involved in colorectal carcinogenesis. Moreover, Omega 3 reduces the 
synthesis of inflammation mediators and prevents carcinogenesis through interaction 
with the signaling pathway NOTCH1/MMP9. Moreover, antioxidants reduce the inflam-
matory process by inhibiting the synthesis of inflammatory mediators, and inhibit the 
mechanisms of cell proliferation by inducing apoptosis. 
In brief, nutraceuticals have gained a huge clinical interest since they could be used 
along with traditional therapy. Bioavailability studies of nutraceutical supplements 
guarantee a correct intake of the substance by oral administration, a matter which 
would not have been possible to have entirely with the consumption of regular food 
only. 
Introduction 
Nutraceutical,  a  “portmanteau”  of  the 
words “nutrition” and “pharmaceutical”, 
is a term used to describe specific foods 
that provide extra health benefits in ad-
dition  to  their  basic  nutritional  value. 
Various studies conducted on nutraceuti-
cal  products  found that this particular 
type of foods have similar properties to 
some medications  with  the  benefit  of 
having  no  side  effects.  Moreover,  re-
cently,  investigators  started  combining 
traditional medical therapy with various 
nutraceutical  foods in order to reduce 
medications side effects. 
The aim of this article is to highlight the 
importance of some nutraceutical prod-
ucts, such as probiotics, prebiotics, es-
sential  fatty acids and antioxidants, in 
preventing and treating some disorders, 
especially, inflammatory bowel diseases 
(IBD) and colorectal cancer (CRC). 
 
IBD and CRC 
IBD’s are chronic bowel disorders that 
include ulcerative  colitis  (UC),  Crohn's 
disease (CD) and Indeterminate Colitis 
(1-3). UC affects primarily the last part 
of the intestine (colon and rectum) while 
CD may affect any part of the gastroin-
testinal tract from mouth to anus, with a 
characteristic abrupt transition between 
unaffected and inflamed mucosal areas 
(2,4).  
On the other hand, CD is characterized 
by a transmural pattern of inflammation 
with alternating periods of remission and 
flare up that often cause the formation of 
fistulae, abscesses and stenosis. UC, in-
stead, affects the mucosa with frequent 
erosions and bleeding (1,4,5). Both dis-
ease  entities  have  similar  symptoms 
such as diarrhea (sometimes mucus-like 
and with blood), abdominal pain, nausea, 
fatigue, anemia and weight loss (3,5).  
The pathogenesis of IBD is multifactorial. 
It involves alterations in the composition 
of  the  intestinal  microbiota  (process 
known as dysbiosis that seems to be the 
"primum  movens"  for  the  genesis  of 
IBD),  alterations  in  the  immune  re-
sponse, genetic (for example the altera-
tion of NOD2 genes) and environmental 
factors  (physical  and  psychological 
stress, surgery, cigarette smoking and 
diet) (2-4).  
The resulting inflammation and dysbiosis 
may also predispose the individual to the 
onset  of  colorectal  cancer.  Colorectal 
cancer is the third most common cancer 
in the world following lung cancer and 
breast cancer (6-8). Its onset, not yet 
fully clarified, could be linked to various 
factors including genetic (only in 20% of 
cases), environmental (exposure to pol-
lutants,  inflammatory  bowel  disease, 
etc.) and lifestyle (physical inactivity, diet 
high in fat and sugar, regular consump-
tion of alcoholic drinks and smoking) (8). 
All of these factors promote an increased 
oxidative stress and reactive oxygen spe-
cies (ROS) (6,9) while maintaining the 
chronic inflammation of the colonic mu-
cosa.  
In turn, the ROS and chronic inflamma-
tion cause alterations at the DNA level 
(aneuploidy,  chromosomal  and  genetic 
instability, punctiform mutations, inser-
tions and deletions) which could promote 
the appearance of dysplastic lesions in 
the colon and subsequent colorectal can-
cer (7-9).  
In addition, ROS could function as cellu-
lar messengers by stimulating the pro-
duction of pro- inflammatory cytokines, 
cell  motility  and  angiogenesis  that  in-
crease the supply of oxygen, nutrients 
and growth factors to the healthy and 
tumor cells (10) . 
 
Probiotics 
Probiotics  are  mixtures  of  bacteria 
(mostly  Lactobacilli,  Bifidobacteria  and 
Enterococci) (11,12), which are normally 
found in the intestine but which can be 
reduced like in dysbiosis (12). 
The  importance  of  probiotics  to  the 
health of the human gut has been well 
documented over the years. These bacte-
rial strains are able to perform various 
functions such as: 
a) Preventing the proliferation and adhe-
sion of pathogenic bacteria to the intesti-
nal lumen (13); 
b) Increase the resistance of cell junc-
tions, and thus reducing the permeability 
of the colonic mucosal barrier by modu-
lating the gene expression of  proteins 
involved in these junctions (14); 
c) Increase the viscosity of mucus cover-
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ing the colonic mucosa, thus preventing 
the colonization of pathogenic bacteria 
(13).  
Probiotics also have a beneficial effect on 
the intestinal  immune system and in-
flammation because they are capable of 
increasing  the  production  of  IgA,  de-
fensins and bacteriocins in the colonic 
lumen. Also, probiotics reduce the prolif-
eration of pathogenic bacteria and the 
synthesis of inflammatory cytokines by 
down regulating the genes involved in 
the synthesis of these cytokines, particu-
larly, NF-kB and its ligand IkB, which re-
main sequestered in the cytoplasm (14). 
 
Prebiotics 
Prebiotics are non-digestible fiber com-
pounds found in some plants as carbohy-
drates. Prebiotics stimulate the growth 
and  activity  of  advantageous  bacteria 
that colonize the colon by acting as sub-
strate for them. The most well-known 
prebiotics  are inulin  and oligofructose, 
which are digested by Lactobacilli  and 
Bifidobacteria in the gut flora leading to 
the reduction of short chain fatty acids 
(SCFAs):  butyric  acid, acetic  acid  and 
others.  These  SCFA’s,  mainly  butyric 
acid,  transported  to  colonocytes,  sup-
press the survival  of  colonic adenoma 
and cancer cells (15). Dietary fiber is fer-
mented by microbes into butyrate inside 
the lumen of the colon and the butyrate 
is then transported into the colonocytes 
(15).  
Prebiotics are involved in various proc-
esses such as the proliferation, differen-
tiation  and  apoptosis  of  colonic  cells. 
They have an anti-inflammatory effect 
and promote resistance to colonization 
by  pathogenic  bacteria  (1,15).  Butyric 
acid also strengthens the defensive bar-
rier of the colon by increasing the pro-
duction of mucins and antimicrobial pep-
tides, and by decreasing the intestinal 
epithelial permeability through increasing 
the expression of the tight junctions pro-
teins (1). 
 
Omega 3 
Omega - 3 (ω3) fatty acids, also called 
polyunsaturated fatty acids (PUFAs), are 
considered essential lipids. Because the 
body is unable to produce them and for 
this reason they should be introduced 
with the diet. They are found in some 
plants oils (such as edible seeds, wal-
nuts, flaxseed and other vegetable oils), 
and in some animals such as fish oils, 
squid oils and salmon (5,16).  
PUFA have several benefits on the human 
organism, they reduce blood triglycerides 
levels,  modestly  lower  blood  pressure 
and  improve  inflammatory  processes 
(17).  The anti-inflammatory  actions  of 
PUFA, when administered orally in the 
form of supplements, are expressed at 
different levels: 
a) Reduction of the chemotaxis of neu-
trophils and monocytes to the inflamma-
tory site by inhibiting the synthesis of 
chemoattractants; 
b) Reduction or inhibition of the eico-
sanoids  synthesis  by  inhibiting  arachi-
donic acid metabolism; 
c) Decrease of T lymphocytes reactivity 
by inhibiting the production of interleukin 
- 2 (IL-2) and the proliferation of T cell 
populations; 
d) Reduction of production of inflamma-
tory  cytokines  by  down-regulating  the 
expression of genes responsible for the 
production of these cytokines; 
e) Downregulation of the expression of 
genes encoding adhesion molecules, and 
thus  reducing  the  interaction  between 
leukocytes and endothelium (16). 
 
Antioxidants 
Antioxidants are substances capable of 
reducing  oxidative  stress  due  to  their 
ability  to  bind  and  neutralize  reactive 
oxygen species (ROS). Polyphenols, the 
main class of antioxidants, can be found 
in various foods such as fruits, vegeta-
bles, cereals, tea, coffee and red wine 
(18).  Once  ingested,  polyphenols  are 
processed and metabolized by the intesti-
nal  microbiota.  They  possess  several 
beneficial effects such as modulation of 
the immune response, improvement of 
cell-cell signaling and tight junction bar-
rier,  reduction  of  oxidative  stress  and 
bowel inflammatory processes (18,19) .  
Polyphenols include different types of an-
tioxidants  such  as  anthocyanins,  that 
give vegetables and fruits their rich col-
ors (20, 21), Anthocyanins, such as the 
catechins (found mainly in green tea), 
tocopherols (also known as vitamin E, 
found in vegetable oils) (22), and res-
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veratrol (found in the peel of red grapes 
and consequently in red wine) (23).  
Other dietary antioxidants includes α and 
β carotene (found in carrots, orange and 
yellow fruits, and vegetables), lycopene 
(found mainly in tomato), lutein and ze-
axanthin (found in green plants) (24). 
 
Discussion 
Currently, the use of nutraceuticals to 
treat IBD symptoms is a very interesting 
and uptodate subject of discussion, espe-
cially regarding the use of omega 3 as an 
anti-inflammatory  agent  and  probiotics 
for restoring the balance of the intestinal 
bacterial  flora.  Nutraceutical  products, 
through the use of antioxidants and anti-
inflammatory substances,  may prevent 
the development of dysplastic lesions in 
the colon and subsequent colorectal can-
cer.  
The main active nutraceuticals and their 
effects on IBD and CRC are summarized 
in Table 1. 
Numerous studies showed that an oral 
supplementation  with  probiotics  im-
proves the inflammatory process in IBD. 
Lactobacillus Rhamnosus strain is capa-
ble of reducing the synthesis of some 
inflammatory mediators involved in IBD 
(13), such as NF-kB (13) and TNF-α (10), 
and increases the production of immu-
noglobulins by intestinal cells (for exam-
ple IgA) (12). Bifidobacteria have also an 
immunomodulatory action, especially on 
CD4+ lymphocytes (13).  
Tomasello et al. showed that probiotics 
when given to patients, mainly Lactoba-
cillus Rhamnosus GG, inhibited the activ-
ity of certain enzymes compared to the 
placebo group (13). The concomitant ad-
ministration  of  Lactobacillus  casei  and 
Bifidobacterium lactis  in animal models 
with induced colitis, reduced the extent 
of the inflammatory reaction in the colo-
nic mucosa, improved all cellular features 
of malignancy, thus proving that probiot-
ics may have a possible role in prevent-
ing CRC (14).  
Other studies showed that mixtures of 
probiotics (Lactobacillus acidophilus and 
Bifidobacterium bifidum) help in improv-
ing the inflammatory status of the colon 
mucosa (12) by down-regulating the ex-
pression of some inflammatory cytokines, 
such  as  IL-6,  IL-1,  IL-8  and  TNF-α 
(13,14).  
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Table 1: Main active nutraceuticals and their effects on IBD and CRC  
IBD AND PERIPHERAL ARTHR ITIS, p. 115 PRUNE BELLY SYNDROME IN A LOW-INCOME COUNTRY, p.6  — www.e bj.org 
Nutraceuticals Effects on IBD Effects on CRC 
Probiotics - Reduction of the synthesis 
of inflammatory mediators; 
-Increased production of im-
munoglobulins; 
- Immunomodulation. 
- Reduction of the synthesis of 
enzymes probably involved in 
colorectal carcinogenesis; 
- May reverse the cellular fea-
tures of malignancy 
Prebiotics - Increased butyrate synthe-
sis; 
- Modulation of intracellular 
pH. 
  
- Reduction of cancerous cells 
proliferation; 
- Restore apoptosis in cells with 
uncontrolled proliferation. 
  
Omega 3 - Reduction of the synthesis 
of inflammatory mediators; 
-Improvement of inflamma-
tory symptoms 
- Counteract the inflammatory 
effect; 
- Prevent carcinogenesis 
through interaction with the 
signaling pathway NOTCH - 1/
MMP9. 
Antioxidants - Reduction of inflammatory 
processes; 
- Inhibition of the synthesis 
of inflammatory mediators. 
- Reduction of oxidative stress; 
- Inhibition of cellular prolifera-
tion mechanisms; 
- Induction of apoptosis. 
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Moreover, patients treated with prebiot-
ics  had  similar  improvements  in  IBD 
symptoms.  Patients  with  CD  when 
treated with prebiotics (5) had an in-
crease in the production of SCFAs, and 
particularly butyric acid. This substance 
is capable of modulating the intracellular 
pH of colonic cells, regulating the gene 
expression and the proliferation of colo-
nic epithelial  cells,  and inhibiting DNA 
synthesis by activating apoptosis in rap-
idly proliferative cells, and thus prevent-
ing the onset of colorectal cancer (15).  
In IBD, the administration of ω3-PUFA 
reduces the damage and the inflamma-
tory reaction at the colonic mucosa by 
reducing the production of eicosanoids 
from arachidonic acid derivatives (16), 
and through their metabolization to 3-
series  prostaglandins  and  5-  series 
thromboxane and leukotriene (1).  
Also,  ω3-PUFA  exert  their  anti-
inflammatory activity through the down - 
regulation of several mechanisms includ-
ing the chemotaxis of lymphocytes, the 
expression  of  adhesion  molecules,  the 
reactivity of T-helper lymphocytes and 
the reactivity of colonic cells by changing 
the composition of the cell  membrane 
which causes transcriptional activation of 
peroxisome proliferator activated recep-
tor  (PPAR)  γ.  Furthermore,  ω3-PUFA 
serves as a substrate for the synthesis of 
proteins that help in reducing the inflam-
matory reactions such as resolvin, pro-
tectin and maresin (17).  
Studies performed on the Eskimo popula-
tion,  largest  consumer  of  ω3-PUFA, 
showed a very low prevalence of IBD in 
the  population,  suggesting  that  these 
fatty acids may play an important role in 
the prevention of IBD (5).  
It is noteworthy that ω3-PUFAs may play 
an important role in colorectal carcino-
genesis.  Fazio  et  al.  demonstrated  in 
mice having colon cancer associated with 
colitis (CAC), that ω3-PUFA interact with 
the signaling pathway NOTCH-1/MMP9. 
This signaling pathway is linked to the 
progression of the carcinogenesis proc-
ess, through an up - regulation of NOTCH 
- 1 and MMP9 resulting from the ongoing 
inflammatory reaction (25).  
Furthermore, several studies supported 
the use of antioxidants, especially epigal-
locatechin-3-O-gallate (EGCG) (that we 
find in green tea) and theaflavin 3,30-
digallate (that we find in black tea), in 
the treatment of IBD (mainly in animals 
models  with  induced  colitis).  They 
showed how these substances were able 
to inhibit various inflammatory signaling 
pathways such as those mediated by Nf-
kB, IkBa and IKK (26,27), with reduced 
production  of  inflammatory  cytokines 
(such as IFN-γ, IL-12, TNF-α, and iNOS 
myeloperoxidase)  (26,27).  They  also 
showed that there was not only a reduc-
tion of inflammatory processes, but also 
a reduction in symptoms such as diar-
rhea and weight loss (26).  
In addition, EGCG can also stimulate and 
enhance  the  synthesis  of  glutathione 
(GSH), one of the most potent antioxi-
dants present in our body, which is capa-
ble to bind and neutralize ROS, thus re-
ducing cellular damage and preventing 
the process of carcinogenesis (28).  
Among  the  polyphenols,  anthocyanins 
have been shown to inhibit tumor growth 
in experimental models of mice. This in-
hibition  can  be  explained  by  several 
mechanisms: arrest of the cell cycle, in-
duction of apoptosis, induction of anti-
proliferative  mechanisms,  reduction  of 
oxidative stress, reduction of inflamma-
tory mechanisms or by their action on 
demethylation mechanisms of tumor sup-
pressor genes (29-31). Likewise,  toco-
pherols exhibit an anti-cancerous activity 
by reducing inflammation and by induc-
ing apoptosis (32).  
For the carotenoids, the action of β - 
carotene on colorectal cancer cells was 
also  investigated.  It  was  shown  that 
these substances reduce the activity of 
an enzyme involved in the increased syn-
thesis of metalloproteinase responsible of 
tumor invasiveness (33). It is also impor-
tant to note that resveratrol exerts an 
action on colorectal cancer cells by block-
ing the up - regulation of K-ras and con-
sequently tumor growth (34). 
 
Conclusions 
This mini review has shown that there is 
a  growing  interest  in  these  functional 
foods. It is clear that many studies are 
still needed since most of them included 
only animal models or cell cultures. In 
brief, nutraceuticals have recently gained 
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a huge clinical interest since they could 
be used simultaneously with traditional 
therapy but with the benefit of not hav-
ing  any  side  effects.  In  addition, 
nutraceuticals  have  gained  some  eco-
nomical interest because pharmaceutical 
companies have started the production 
of these supplements on a large scale.  
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